Home
overview
Benefits of attending:
  • · Genomics: learn about biological databases and genomically-derived drugs
  • · Treatments: gain insight into cutting edge research
  • · Complications: keep up to date with the latest treatments
  • · Transplantation: find out about the potential of islet cell transplantation
  • · Drug delivery: discover the latest developments
  • · Networking: exchange ideas with key players in the field

    A unique opportunity to learn from leading experts including:

  • · Dr Michael Trautmann, Senior Clinical Research Physician, Eli Lilly
  • · Dr Raffaella Balena, Clinical Research & Licensing Liaison, Roche
  • · Palle Serup, Head of Department, Hagedorn Research Institute, Novo Nordisk
  • · Dr Agata Ptaszynska, Director, Clinical Development & Evaluation, Cardiovascular & Immunology, Bristol-Myers Squibb
  • · Dr Sean O’Connell, Director, Medical Affairs, Novartis
  • · Dr Alain Baron, Vice President, Clinical Research, Amylin
  • · Dr Pankaj Modi, Vice President, Research & Development, Generex
  • · Dr Andrew Nichols, Senior Director, Physiology & Pharmacology, Metabolic Diseases, Millennium
  • Conference programme

    8:30 Registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor David Leslie

    Professor David Leslie, Professor, Diabetes & Autoimmunity, Queen Mary College, University of London

    9:10 OVERVIEW

    Professor David Leslie

    Professor David Leslie, Professor, Diabetes & Autoimmunity, Queen Mary College, University of London

  • Incidence of diabetes in the world today
  • Emerging concerns
  • Prevalence of diabetes-related complications
  • Unmet clinical needs
  • Recommendations for future strategies
  • 9:40 GLUCOCORTICOID RECEPTOR ANTAGONIST

    Lars Öhman

    Lars Öhman, Director, Marketing & Business Development, Karo Bio

  • Limitations of existing treatments for diabetes
  • Liver function and glucose production in diabetes
  • Role of glucocorticoids
  • Development of liver selective glucocorticoid antagonists
  • Advanced structure determination programme
  • 10:20 MITOCHONDRIAL DRUG TARGETS FOR TYPE 2 DIABETES

    Christen M Anderson

    Christen M Anderson, Director, Metabolic Diseases, Mitokor

    11:00 Morning Coffee

    11:20 ORALLY ACTIVE ANTI-DIABETIC PLANT EXTRACTS

    Dr Maya Gowri

    Dr Maya Gowri, Manager, Business Development, Calyx Therapeutics

  • Novel small molecules
  • Effect on blood glucose, TG, FFA and cholesterol levels
  • Advantages over other anti-diabetic treatments
  • Clinical trials
  • Future developments
  • 12:00 BIOLOGICAL DATABASES

    Holger Karas

    Holger Karas, Senior Vice President, Business Development, BIOBASE

  • Identification of variable DNA points on the genome
  • Relevance to diagnosis of diabetes
  • Application to custom-made medications
  • ‘Transfac’ - transcription factor database
  • 12:40 Lunch Sponsored by Millennium

    14:00 GENOMICALLY-DERIVED DRUGS

    Dr Andrew Nichols

    Dr Andrew Nichols, Senior Director, Physiology & Pharmacology, Metabolic Diseases, Millennium

  • Strategies for novel target discovery and validation
  • Drug discovery approaches for novel targets
  • Development challenges for genomics-based drug discovery
  • 14:40 GLUCOKINASE ACTIVATORS

    Dr Raffaella Balena

    Dr Raffaella Balena, Clinical Research & Licensing Liaison, Roche

  • Scientific rationale
  • Mechanism of action
  • Effects of GK activators in islets
  • In vivo pharmacology
  • 15:20 ISLET TRANSPLANTATION

    Palle Serup

    Palle Serup, Head of Department, Hagedorn Research Institute, Novo Nordisk

  • Prolonged graft survival time with glucocorticoid-free immunosuppressive therapies
  • Stem cells as a source of beta cell transplantation
  • What can be learned from normal beta cell development?
  • 16:00 Afternoon Tea

    16:20 TRANSGENIC TECHNOLOGY AND DIABETES

    Marilyn Moore

    Marilyn Moore, Head, Immunology, PPL Therapeutics

  • ‘Knock-out’ pigs for cell and organ transplantation
  • Alpha 1,3 galatosyl transferase gene knockout for avoidance of hyperacute rejection
  • Solutions to delayed xenograft rejection, coagulopathy and chronic T cell rejection
  • Future implications
  • 17:00 ARTIFICIAL PANCREAS

    Professor Bruno Reihl

    Professor Bruno Reihl, Chief Technology Officer, Disetronic Medical Systems

  • Nature of device
  • Comparisons of glucose sensor readings with finger-prick tests
  • Precise insulin dosages
  • Running on ‘autopilot’
  • Hurdles to be overcome
  • Outlook for the future
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Richard Carr

    Dr Richard Carr, Scientific Vice President, New Antidiabetic Agents, Novo Nordisk

    9:10 BASIC ENDOCRINOLOGY

    Professor Jens Juul Holst

    Professor Jens Juul Holst, Professor, Medical Physiology, University of Copenhagen

  • GLP1 as an incretin hormone

    Physiological actions of GLP1

  • Clinical experiences with natural GLP1

    Why GLP1 is unsuitable for treatment

  • GLP1 as a basis for drug development
  • Turning a hormone into a useful drug
  • Therapeutic potential

    GLP1 receptor

  • Ligand-binding properties

    Signal transduction

  • 10:00 GLUCAGON-LIKE PEPTIDE 1

    Dr Michael Trautmann

    Dr Michael Trautmann, Medical Advisor, Eli Lilly

  • Effect on insulin secretion
  • Pharmacokinetic properties
  • Insolinotropic properties
  • Glucagonostatic properties
  • Dose-response relationship
  • Effects on gastric emptying
  • 10:50 Morning Coffee

    11:20 GLP1-LIKE PEPTIDE

    Dr Alain Baron

    Dr Alain Baron, Vice President, Clinical Research, Amylin

  • Duration of action
  • Glucose concentration and insulin secretion
  • Entry of ingested nutrients into bloodstream
  • Food consumption in obesity
  • Blood glucose levels
  • Route of delivery
  • 12:00 DIPEPTIDYL PEPTIDASE IV (DPPIV) - INHIBITORS

    Dr David Holmes

    Dr David Holmes, Clinical Programme Leader, Novartis

  • Why use DPP-IV inhibitors to treat type 2 diabetes?
  • Effect on insulin secretion and hyperglycaemia in animals
  • Effects in pre-clinical and clinical studies
  • Therapeutic potential
  • 12:40 Lunch

    14:00 DEVELOPMENT OF ORAL DPP IV INHIBITORS FOR DIABETES TREATMENT

    Dr Hans-Ulrich Demuth

    Dr Hans-Ulrich Demuth, Chief Scientific Officer, probiodrug

  • Effect on glucose tolerance
  • Control of incretins and serum glucagon
  • Safety and tolerability
  • Therapeutic potential
  • 14:40 INSULIN-LIKE GROWTH FACTOR (IGF) HORMONE

    Dr Douglas Ishii

    Dr Douglas Ishii, Chief Executive Officer, Aurogen

  • Neurotrophic properties of IGFs

    Reduced IGF gene expression in diabetes

  • Effects of IGF replacement on diabetic neuropathy
  • IGF treatment is effective despite hyperglycaemia
  • Clinical safety profile at IGF replacement doses
  • IGF uptake across blood-central nervous system-barrier
  • Effect of systemic IGF treatment on diabetic and other CNS disorders
  • 15:20 Afternoon Tea

    15:40 RENAL ANAEMIA IN DIABETES

    Dr Jonathan Emmerson

    Dr Jonathan Emmerson, Business Director, Ortho Biotech Europe

  • Relationship between diabetes, renal disease and anaemia
  • Consequences of renal anaemia on morbidity and mortality
  • Potential benefits of epoetin treatment
  • Future outlook
  • 16:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.